Send to

Choose Destination
Medicine (Baltimore). 2019 Jun;98(25):e16074. doi: 10.1097/MD.0000000000016074.

Sorafenib with concurrent multiple-line therapies improves overall survival in advanced stage hepatocellular carcinoma.

Hsiao P1, Hsieh KC2, Chen YS2,3, Hsu CC1,3,4,5, Lo GH1,3,4, Li YC3, Hsieh PM2, Lin HY2,3,6, Wu TC1, Yeh JH1, Lin CW1,3,4,5,6,7,8.

Author information

Division of Gastroenterology and Hepatology, E-Da Dachang Hospital.
Department of Surgery, E-Da Hospital, I-Shou University.
School of Medicine, College of Medicine, I-Shou University, Kaohsiung.
Division of Gastroenterology and Hepatology, Department of Medicine.
Health Examination Center.
Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung.
School of Chinese Medicine, College of Chinese Medicine, China Medical University.
Research Center for Traditional Chinese Medicine, China Medical University Hospital, Taichung, Taiwan.


The efficacy of sorafenib in combination with transarterial chemoembolization (TACE) or multiple-line therapies in patients with advanced hepatocellular carcinoma (HCC) remains unclear. This study aimed to investigate the overall survival (OS) of patients with advanced HCC in response to different combination therapies.We analyzed the treatment and OS of 401 patients with Barcelona clinic liver cancer stage C HCC between 2012 and 2017. Mortality was analyzed using multivariate Cox regression, and OS was analyzed by the Kaplan-Meier method.The mean age was 59 years and males were predominant. During a median follow-up time of 8.6 months (range, 1-80 months), 346 (86.2%) patients died. In the multivariate Cox regression analysis, primary tumor size ≥5 cm, serum alpha-fetoprotein ≥200, and serum albumin ≥3.5 were significantly associated with mortality. In addition, compared with sorafenib alone, multiple-line treatments with sorafenib and multiple-line treatments without sorafenib yielded significantly decreased mortality. In the Kaplan-Meier analysis, sorafenib with TACE, multiple-line treatments with sorafenib, third-line treatments with sorafenib, and multiple-line treatments without sorafenib yielded a significantly better median OS than sorafenib alone.Sorafenib with concurrent multiple-line therapies significantly improved OS. These combination therapies will provide important information for immunotherapy combination with locoregional therapies in advanced HCC.

[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center